Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME. Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) , Lung Cancer: 2026
Bleiberg BA, Scholes DG, Reed-Guy L, Dravid D, Sun LL, Singh AP, Cohen RB, Langer CJ, Marmarelis ME, Aggarwal C. The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing , J Liq Biopsy, 12: 2026,100461
Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ. Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy , Am J Clin Oncol: 2025
Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT. Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911 , Int J Radiat Oncol Biol Phys, 124: 2025,50-60
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status , Clin Lung Cancer: 2025
Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L. Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC , JTO Clin Res Rep, 6: 2025,100851
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME. Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis , Lung Cancer, 203: 2025
Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C. Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy , Clin Lung Cancer, 26(2): 2025,158-163.e2
Stalker M, Walker SL, Lebow E, Pai EL, Watts A, Hwang WT, Banihashemi A, Anderson E, Roshkovan L, Katz SI, Litzky L, Haas AR, Singhal S, Langer CJ, Cengel K, Marmarelis ME. Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy , JTO Clin Res Rep, 6: 2025,100823
Stalker M, Marmarelis M, Langer C, Cohen RB, Singh A, Aggarwal C, Sun L. Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC , Clin Lung Cancer, 26(2): 2025,124-130.e1
